LAVIPHARM S.A. NA EO 1 (BXA0) - Net Assets
Based on the latest financial reports, LAVIPHARM S.A. NA EO 1 (BXA0) has net assets worth €52.97 Million EUR (≈ $61.92 Million USD) as of December 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€125.48 Million ≈ $146.70 Million USD) and total liabilities (€72.52 Million ≈ $84.78 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of LAVIPHARM S.A. NA EO 1 to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €52.97 Million |
| % of Total Assets | 42.21% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 8.87 |
LAVIPHARM S.A. NA EO 1 - Net Assets Trend (2021–2024)
This chart illustrates how LAVIPHARM S.A. NA EO 1's net assets have evolved over time, based on quarterly financial data. Also explore LAVIPHARM S.A. NA EO 1 balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for LAVIPHARM S.A. NA EO 1 (2021–2024)
The table below shows the annual net assets of LAVIPHARM S.A. NA EO 1 from 2021 to 2024. For live valuation and market cap data, see how much is LAVIPHARM S.A. NA EO 1 worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €52.97 Million ≈ $61.92 Million |
+23.84% |
| 2023-12-31 | €42.77 Million ≈ $50.00 Million |
+6.09% |
| 2022-12-31 | €40.31 Million ≈ $47.13 Million |
+505.69% |
| 2021-12-31 | €-9.94 Million ≈ $-11.62 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to LAVIPHARM S.A. NA EO 1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 13826000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €76.83 Million | 145.02% |
| Total Equity | €52.98 Million | 100.00% |
LAVIPHARM S.A. NA EO 1 Competitors by Market Cap
The table below lists competitors of LAVIPHARM S.A. NA EO 1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Third Harmonic Bio Inc.
NASDAQ:THRD
|
$242.79 Million |
|
Becamex Infrastructure Development JSC
VN:IJC
|
$242.79 Million |
|
Escalade Incorporated
NASDAQ:ESCA
|
$242.81 Million |
|
AME Elite Consortium Bhd
KLSE:5293
|
$242.84 Million |
|
Shin Shin Natural Gas Co Ltd
TW:9918
|
$242.56 Million |
|
Sam Yung Tradi
KO:002810
|
$242.51 Million |
|
Vertical Aerospace Ltd
NYSE:EVTL
|
$242.48 Million |
|
Naturgy BAN SA
BA:GBAN
|
$242.39 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in LAVIPHARM S.A. NA EO 1's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 42,737,000 to 52,976,000, a change of 10,239,000 (24.0%).
- Net income of 8,982,000 contributed positively to equity growth.
- Other factors increased equity by 1,257,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €8.98 Million | +16.95% |
| Other Changes | €1.26 Million | +2.37% |
| Total Change | €- | 23.96% |
Book Value vs Market Value Analysis
This analysis compares LAVIPHARM S.A. NA EO 1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.42x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €-0.55 | €1.39 | x |
| 2022-12-31 | €0.24 | €1.39 | x |
| 2023-12-31 | €0.25 | €1.39 | x |
| 2024-12-31 | €0.31 | €1.39 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently LAVIPHARM S.A. NA EO 1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 16.95%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.96%
- • Asset Turnover: 0.42x
- • Equity Multiplier: 2.37x
- Recent ROE (16.95%) is above the historical average (5.85%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 0.00% | 4.34% | 0.75x | 0.00x | €2.72 Million |
| 2022 | 2.07% | 2.14% | 0.34x | 2.83x | €-3.19 Million |
| 2023 | 4.38% | 3.91% | 0.42x | 2.69x | €-2.40 Million |
| 2024 | 16.95% | 16.96% | 0.42x | 2.37x | €3.68 Million |
Industry Comparison
This section compares LAVIPHARM S.A. NA EO 1's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $676,868,481
- Average return on equity (ROE) among peers: -100.00%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| LAVIPHARM S.A. NA EO 1 (BXA0) | €52.97 Million | 0.00% | 1.37x | $242.59 Million |
| Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) | $5.52 Billion | 11.33% | 0.42x | $635.99 Million |
| AYURCANN HOLDINGS CORP. (3ZQ0) | $534.88K | -741.80% | 26.77x | $113.81K |
| LORDS CO. WORLDW. HOLD. (4XM) | $-1.01 Million | 0.00% | 0.00x | $134.78K |
| EQL PHARMA AB (7JK) | $123.63 Million | 25.52% | 0.92x | $148.83 Million |
| Alkermes plc (8AK) | $1.11 Billion | -4.33% | 0.82x | $5.00 Billion |
| OPTIMI HEALTH CORP. (8BN) | $6.57 Million | -56.49% | 1.32x | $17.99 Million |
| LABIANA HEALTH S.A.EO-10 (8RK) | $2.57 Million | 9.87% | 19.25x | $40.60 Million |
| CANNABIS POLAND AB ZY-10 (8TE) | $321.96K | -209.89% | 1.07x | $1.75 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $91.63 Million |
| CRAFTPORT CANNABIS CORP. (BBW0) | $-3.18 Million | 0.00% | 0.00x | $1.45 Million |
About LAVIPHARM S.A. NA EO 1
Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally. The company offers pharmaceutical products for cardiology, oncology-urology, central nervous system, chronic pain, and self- treatment. It also provides prescription medicines and… Read more